drugset / Trial / NCT05348993
Single or Repeat Dose of G03-52-01 in Adult Subjects
Phase 2
Completed
622 enrolled
U.S. Army Medical Research and Development Command
United States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase 2, randomized, double-blind, placebo-controlled single or repeat dose trial
Timeline
- Start
- 2022-06-15
- Primary completion
- 2025-02-18
- Completion
- 2025-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G03-52-01 | Unknown | 50 mg | Intramuscular |
| Subject | G03-52-01 | Unknown | 100 mg | Intramuscular |